Daniel Estes, Ph.D.

General Partner

Dan is a General Partner on the Frazier Life Sciences team and has been involved with investing in and building many of Frazier’s biopharmaceutical portfolio companies over the past 11 years.

Dan joined Frazier Healthcare Partners in 2011 and focuses on investments in both development-stage and commercial-stage pharmaceutical companies. He has led Frazier’s investments in, and serves on the boards of, Cirius Therapeutics, Hummingbird Bioscience, Inipharm, and Lengo Therapeutics. He previously served on the boards of Arcutis Biotherapeutics (NASDAQ: ARQT, co-founder) and Semnur Pharmaceuticals (acquired by Scilex), and led Frazier’s investment in Tarsus Pharmaceuticals (NASDAQ: TARS).

Dan has also been involved in Frazier’s investments in Acerta Pharma BV (acquired by AstraZeneca), Tobira Therapeutics (acquired by Allergan), Ignyta (acquired by Roche), Iovance (NASDAQ: IOVA), Vaxcyte (NADAQ: PCVX), and PreCision Dermatology (acquired by Valeant).

Prior to joining Frazier, Dan was a management consultant with McKinsey & Company’s healthcare practice, where he led teams that advised leading global pharmaceutical and biotechnology companies on R&D strategy and business development strategy. He received his Ph.D. in Biomedical Engineering from the University of Michigan and holds a B.S. in Electrical Engineering from Stanford University, where he is a member of Tau Beta Pi.

In 2018, Dan was named a “40-and-under Silicon Valley biotech investing star” by Business Insider.

Menlo Park

Stanford University (B.S.)
University of Michigan (Ph.D.)

Year Joined
Social Media